Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2014, Article ID 138963, 3 pages
http://dx.doi.org/10.1155/2014/138963
Case Report

The Bee Sting That Was Not: An Unusual Case of Hymenoptera Anaphylaxis Averted in a Patient Treated with Omalizumab for Asthma

1Department of Internal Medicine, Madigan Army Medical Center, 9040 Fitzsimmons Drive, Tacoma, WA 98431, USA
2Department of Pulmonary and Critical Care Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive No. 3600, San Antonio, TX 78219, USA
3Department of Pulmonary, Sleep and Critical Care Medicine, Madigan Army Medical Center, 9040 Fitzsimmons Drive, Tacoma, WA 98431, USA

Received 18 April 2014; Revised 17 July 2014; Accepted 21 July 2014; Published 12 August 2014

Academic Editor: Luis García-Marcos

Copyright © 2014 Evelyn M. Slaughter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. C. Thomson and R. Chaudhuri, “Omalizumab: clinical use for the management of asthma,” Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, vol. 6, no. 1, pp. 27–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Shankar and A. A. Petrov, “Omalizumab and hypersensitivity reactions,” Current Opinion in Allergy and Clinical Immunology, vol. 13, no. 1, pp. 19–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. C. Bell and D. J. Jackson, “Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab,” Annals of Allergy, Asthma and Immunology, vol. 108, no. 5, pp. 383–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Kontou-Fili and C. I. Filis, “Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis,” Allergy, vol. 64, no. 9, pp. 1384–1385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Jones, S. R. Marney Jr., and J. M. Fahrenholz, “Idiopathic anaphylaxis successfully treated with omalizumab,” Annals of Allergy, Asthma and Immunology, vol. 101, no. 5, pp. 550–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Y. M. Leung, H. A. Sampson, J. W. Yunginger et al., “Effect of anti-IgE therapy in patients with peanut allergy,” The New England Journal of Medicine, vol. 348, no. 11, pp. 986–993, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. H. M. Tartibi, A. R. Majmundar, and D. A. Khan, “Successful use of omalizumab for prevention of fire ant anaphylaxis,” Journal of Allergy and Clinical Immunology, vol. 126, no. 3, pp. 664–665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. B. Schwartz, “Diagnostic value of tryptase in anaphylaxis and mastocytosis,” Immunology and Allergy Clinics of North America, vol. 26, no. 3, pp. 451–463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. V. Kopp, E. Hamelmann, S. Zielen et al., “Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma,” Clinical and Experimental Allergy, vol. 39, no. 2, pp. 271–279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Maurer, K. Rosén, H. J. Hsieh et al., “Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria,” The New England Journal of Medicine, vol. 368, pp. 924–935, 2013. View at Google Scholar
  11. M. Massanari, H. Nelson, T. Casale et al., “Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. 383–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Ivyanskiy, C. Sand, and S. F. Thomsen, “Omalizumab for chronic urticaria: a case series and overview of the literature,” Case Reports in Dermatology, vol. 4, no. 1, pp. 19–26, 2012. View at Publisher · View at Google Scholar · View at Scopus